Action PSTX POSEIDA THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Poseida Therapeutics, Inc.

Actions

PSTX

US73730P1084

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
2,69 USD -2,89 % Graphique intraday de Poseida Therapeutics, Inc. -10,03 % -19,94 %
14/05 Poseida Therapeutics réduit sa perte nette au premier trimestre et augmente son chiffre d'affaires MT
14/05 Poseida Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Malin Corp investee signs agreement with Astellas Pharma
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PSTX
  4. Actualités Poseida Therapeutics, Inc.
  5. Autres langues